DEMADEX Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Demadex, and when can generic versions of Demadex launch?

Demadex is a drug marketed by Roche and Norvium Bioscience and is included in two NDAs.

The generic ingredient in DEMADEX is torsemide. There are sixteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the torsemide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Demadex

A generic version of DEMADEX was approved as torsemide by STRIDES PHARMA on May 27^th, 2003.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for DEMADEX?
What are the global sales for DEMADEX?
What is Average Wholesale Price for DEMADEX?

Summary for DEMADEX

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	126
Clinical Trials:	7
Patent Applications:	4,694
Drug Prices:	Drug price information for DEMADEX
What excipients (inactive ingredients) are in DEMADEX?	DEMADEX excipients list
DailyMed Link:	DEMADEX at DailyMed

Drug patent expirations by year for DEMADEX

Recent Clinical Trials for DEMADEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
New York City Health and Hospitals Corporation	Phase 4
Sarfez Pharmaceuticals, Inc.	Phase 1
Roxane Laboratories	N/A

See all DEMADEX clinical trials

US Patents and Regulatory Information for DEMADEX

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	DEMADEX	torsemide	SOLUTION;INTRAVENOUS	020137-002	Aug 23, 1993		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-002	Aug 23, 1993		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Roche	DEMADEX	torsemide	SOLUTION;INTRAVENOUS	020137-001	Aug 23, 1993		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-001	Aug 23, 1993		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-004	Aug 23, 1993		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for DEMADEX

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-002	Aug 23, 1993	⤷ Sign Up	⤷ Sign Up
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-004	Aug 23, 1993	⤷ Sign Up	⤷ Sign Up
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-004	Aug 23, 1993	⤷ Sign Up	⤷ Sign Up
Roche	DEMADEX	torsemide	SOLUTION;INTRAVENOUS	020137-002	Aug 23, 1993	⤷ Sign Up	⤷ Sign Up
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-001	Aug 23, 1993	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for DEMADEX

See the table below for patents covering DEMADEX around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Mexico	4679		⤷ Sign Up
German Democratic Republic	259858	VERFAHREN ZUR HERSTELLUNG VON KRISTALLINEM TORASEMID DER MODIFIKATION I	⤷ Sign Up
Japan	H0415205		⤷ Sign Up
Yugoslavia	42409		⤷ Sign Up
Japan	H055810		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for DEMADEX

Recent Clinical Trials for DEMADEX

Make Better Decisions: Try a trial or see plans & pricing